97-983. Rhone-Poulenc Ag Company; Pesticide Tolerance Petition Filing  

  • [Federal Register Volume 62, Number 10 (Wednesday, January 15, 1997)]
    [Notices]
    [Pages 2149-2154]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 97-983]
    
    
    -----------------------------------------------------------------------
    
    ENVIRONMENTAL PROTECTION AGENCY
    [PF-686; FRL-5580-3]
    
    
    Rhone-Poulenc Ag Company; Pesticide Tolerance Petition Filing
    
    AGENCY: Environmental Protection Agency (EPA).
    
    ACTION: Notice of filing.
    
    -----------------------------------------------------------------------
    
    SUMMARY: This notice announces the filing of pesticide petitions 
    proposing to increase and decrease tolerances for ethephon in or on 
    cottonseed, meat and milk, and proposes establishing new tolerances for 
    cotton gin trash and poultry. The summary was prepared by the 
    petitioner, Rhone-Poulenc Ag Company.
    
    DATES: Comments, identified by the docket number [PF-686], must be 
    received on or before, February 14, 1997.
    
    ADDRESSES: By mail, submit written comments to Public Response and 
    Program Resources Branch, Field Operations Division (7506C), Office of 
    Pesticide Programs, Environmental Protection Agency, 401 M St. SW., 
    Washington, DC 20460. In person, bring comments to Rm. 1132, CM #2. 
    1921 Jefferson Davis Highway, Arlington, VA 22202.
        Comments and data may also be submitted electronically be sending 
    electronic mail (e-mail) to: opp-docket@epamail.epa.gov. Electronic 
    comments must be submitted as an ASCII file avoiding the use of special 
    characters and any form of encryption. Comments and data will also be 
    accepted on disks in WordPerfect in 5.1 file format or ASCII file 
    format. All comments and data in electronic form must be identified by 
    docket number [PF-686]. Electronic comments on this notice may be filed 
    online at many Federal Depository Libraries. Additional information on 
    electronic submissions can be found below this document.
        Information submitted as a comments concerning this document may be 
    claimed confidential by marking any part or all of that information as 
    ``Confidential Business Information'' (CBI). CBI should not be 
    submitted through e-mail. Information marked as CBI will not be 
    disclosed except in
    
    [[Page 2150]]
    
    accordance with procedures set forth in 40 CFR part 2. A copy of the 
    comment that does not contain CBI must be submitted for inclusion in 
    the public record. Information not marked confidential may be disclosed 
    publicly by EPA without prior notice. All written comments will be 
    available for public inspection in Rm. 1132 at the address given above, 
    from 8:30 a.m. to 4 p.m., Monday through Friday, excluding legal 
    holidays.
    
    FOR FURTHER INFORMATION CONTACT: Philip V. Errico, Acting Product 
    Manager (PM 22), Rm., 229, CM #2, 1921 Jefferson Davis Highway, 
    Arlington, VA., 703-305-5540, e-mail: errico.philip@epamail.epa.gov.
    
    SUPPLEMENTARY INFORMATION: EPA has received pesticide petitions (PP) 
    1H5603 (originally published in the Federal Register of April 3, 1991, 
    (56 FR 13641)), and 6F4743 from Rhone-Poulenc AG Company, P.O. Box 
    12014, Research Triangle Park, NC 27709 proposing pursuant to section 
    408(d) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. section 
    346a(d), to amend 40 CFR part 180 by increasing the established 
    tolerances for residues of the plant growth regulator, ethephon, (2-
    chloroethyl phosphonic acid, in or on the raw agricultural commodities 
    (RACs) cottonseed from 4.0 parts per million (ppm) to 6.0 ppm; meat by-
    products (except kidney) of cattle, goats, hogs, horses, and sheep from 
    0.1 to 0.2 ppm; by decreasing established tolerances for ethephon in or 
    on RACs milk from 0.1 ppm to 0.01 ppm, fat of cattle, goats, hogs, 
    horses, and sheep from 0.1 ppm to 0.02 ppm; and by establishing 
    tolerances for ethephon in or on cotton gin byproducts to 180 ppm; 
    kidney of cattle, goats, hogs, horses, and sheep at 1.0 ppm; eggs at 
    0.002 ppm; poultry meat at 0.01 ppm; poultry liver at 0.05 ppm; poultry 
    fat at 0.02 ppm; and poultry meat byproducts (except liver at 0.01 ppm. 
    The proposed analytical method is analysis for ethylene release.
        Pursuant to the section 408(d)(2)(A)(i) of the FFDCA, as recently 
    amended by the Food Quality Protection Act, Rhone-Poulenc AG Company 
    has submitted the following summary of information, data and arguments 
    in support of their pesticide petition. This summary was prepared by 
    Rhone-Poulenc AG Company and EPA has not fully evaluated the merits of 
    the petition. EPA edited the summary to clarify that the conclusions 
    and arguments were the petitioner's and not necessarily EPA's and to 
    remove certain extraneous material.
    
    I. Petition Summary
    
    A. Residue Chemistry
    
        1. Plant metabolism. The qualitative nature of the residue in 
    plants is adequately understood based on tomato, cantaloupe, apple, 
    fig, pineapple, tobacco, grape, walnut, filbert, cherry, tangerine and 
    lemon metabolism data. Ethephon degrades to ethylene phosphate and 
    chloride. Data indicate that proximal and distal translocation of 
    ethephon to fruits may occur following application to leaves. The 
    residue of concern in plants is ethephon.
        2. Analytical method. Adequate methods for purposes of enforcement 
    of ethephon tolerances in plant commodities, ruminant tissues, and milk 
    are available. The Amchem-Plant Method (PAM, Vol. II, Method I) is the 
    recommended method for enforcement purposes for plant commodities and 
    processed products other than wheat and barley straw. The Amchem-Cereal 
    Method (forwarded to FDA for inclusion in the PAM, Vol. II, Method I) 
    is the recommended method for enforcement purposes for wheat and barley 
    straw. The Union Carbide-Animal Method (forwarded to FDA for inclusion 
    in the PAM, Vol. II, Method III) is the recommended method for 
    enforcement purposes for milk and animal tissues. These methods employ 
    diazomethane as a methylating agent. A new plant and animal method has 
    been submitted for enforcement purposes that does not employ 
    diazomethane. The method principally involves the decomposition of 
    ethephon to ethylene to determine the residues of ethephon. An 
    independent lab validation of this method is in review at EPA.
        3. Magnitude of residues. Residue studies have been conducted to 
    support ethephon registrations on: cotton, apples, cherries, tomatoes, 
    wheat, barley, peppers, grapes, tobacco, walnuts, almonds, 
    blackberries, cantaloupe, pineapple, sugarcane and macadamia nuts. In 
    addition, IR-4 is conducting work to support new uses on blueberries, 
    coffee, cranberries, figs and guavas. All residue data requirements 
    cited in the ethephon RED have been submitted to EPA. As a result of 
    this work, increased tolerances have been proposed for cottonseed (6 
    ppm, PP 6F4743) and cotton gin by-products (180 ppm, amendment to PP 
    1H5603). As part of the reregistration process, the following 
    tolerances will be revoked: cucumbers, filberts, lemons, pineapple 
    forage and fodder, pumpkins, tangerines, tangerine hybrids and 
    sugarcane molasses. The tolerances for residues of ethephon in or on 
    food and feed commodities are currently based in terms of ethephon per 
    se. Processing studies have been conducted on apples, barley, 
    cottonseeds, grapes, pineapples, tomatoes, and wheat and are deemed 
    adequate to determine the extent to which residues of ethephon 
    concentrate in food/feed items upon processing of the raw agricultural 
    commodity. Data indicate that ethephon residues concentrate in apple 
    juice, dried apple pomace, barley hulls, cottonseed meal, grape juice, 
    raisins, raisin waste, dried grape pomace, pineapple bran and pulp, 
    dried tomato pomace, wheat bran, wheat shorts and germ and red dog. 
    Available apple processing data indicate that residues of ethephon do 
    not concentrate in wet apple pomace. Therefore, a feed additive 
    tolerance on apple pomace is not required. Available tomato processing 
    data indicate that residues of ethephon do not concentrate in tomato 
    paste and, therefore, no tolerance is needed. Pineapple processing data 
    indicate that residues of ethephon concentrate in dried pineapple bran 
    (5.3X; no longer a processed commodity) and wet pulp (1.2X), but do not 
    concentrate in juice, syrup, and slices. No feed additive tolerance for 
    residues of ethephon in processed pineapple is required. As a result of 
    a recent cow feeding study, new animal tolerances have been proposed. 
    The following tolerances have been proposed for cattle, goat, horses, 
    and sheep: meat - 0.02 ppm; meat byproducts (except kidney) - 0.20 ppm; 
    kidney - 1.0 ppm; fat 0.02 ppm, and milk (cow and goat) - 0.01 ppm. 
    Following a hen feeding study, new tolerances were proposed for 
    poultry: poultry meat - 0.01 ppm; poultry meat byproducts (except 
    liver) - 0.01 ppm; poultry fat - 0.02 ppm; poultry liver - 0.05 ppm; 
    and eggs - 0.002 ppm.
    
    B. Toxicology Profile
    
        1. Acute toxicity--Ethephon technical. A complete battery of acute 
    toxicity studies for ethephon technical was completed. The acute oral 
    toxicity study resulted in a LD50 of 1,600 mg/kg for both sexes. 
    The acute dermal toxicity in rabbits resulted in an LD50 in either 
    sex of greater than 5000 mg/kg. The acute inhalation study in rats 
    resulted in a LC50 of 4.52 mg/l. Ethephon was corrosive to the 
    skin of rabbits in the primary dermal irritation study. Therefore, the 
    primary eye irritation study in rabbits was not required. The dermal 
    sensitization study in guinea pigs indicated that ethephon is not a 
    sensitizer. Based on the results of the dermal irritation study, and 
    the anticipated results in an eye irritation study, ethephon technical 
    is placed in toxicity Category I.
    
    [[Page 2151]]
    
        Conclusion: Based on the acute toxicity data cited above it is 
    concluded that ethephon technical does not pose any acute dietary 
    risks.
        2. Genotoxicity--Ethephon technical. The potential for genetic 
    toxicity of ethephon was evaluated in several assays. The compound was 
    found to be mutagenic in strain TA-1535 with and without S9 activation 
    in the Ames assay. In the in vitro chromosomal aberrations study with 
    Chinese hamster ovary cells, ethephon was negative. Ethephon was tested 
    for unscheduled DNA synthesis in the rat hepatocyte system and was 
    found to be negative. The weight of evidence suggests that this 
    material is non-genotoxic.
        Conclusions: Based on the data cited above, the weight of evidence 
    indicates that ethephon technical does not pose a risk of mutagenicity 
    or genotoxicity.
        3. Reproductive and developmental toxicity. Ethephon has been 
    tested for reproductive toxicity in rats and developmental toxicity in 
    both rats and rabbits (two studies in each species). The results of 
    these studies are summarized below:
        a. In a two generation reproduction study, 28 Sprague-Dawley rats 
    per sex per dose were administered 0, 300, 3,000, or 30,000 ppm (0,15, 
    150, or 1,500 mg/kg/day) of ethephon in the diet. For the offspring, a 
    NOEL of 15 mg/kg/day and a LOEL of 150 mg/kg/day was established based 
    on decreased body weight gain in the females at 150 mg/kg/day and in 
    both sexes at 1,500 mg/kg/day. No effects were observed on fertility, 
    gestation, mating, organ weights, or histopathology in any generation.
        b. In rats, ethephon was administered by gavage at doses of 0, 20, 
    600, or 1,800 mg/kg for gestation days 6 through 15. At 1,800 mg/kg/
    day, 14 of the 24 treated female rats died. No toxic effects were 
    observed at lower doses. The NOEL for maternal and developmental 
    toxicity was 600 mg/kg/day. In a second study, rats were dosed by 
    gavage at 0, 125, 250, or 500 mg/kg/day on days 6 through 15 of 
    gestation. No toxic effects were observed at any dose. The NOEL for 
    maternal and developmental toxicity was 500 mg/kg/day.
        c. In rabbits, ethephon was administered by gavage at doses of 0, 
    50, 100, and 250 mg/kg for gestation days 6 through 19. The number of 
    does with live fetuses were 10, 12, 8, and 5, respectively. Resorptions 
    were increased at 100 mg/kg/day and statistically significantly 
    increased at 250 mg/kg/day. At 250 mg/kg/day, does were depressed, 
    ataxic, showed an increase of clinical observations and gross pathology 
    in the gut. The NOEL for maternal toxicity was 50 mg/kg/day and the 
    NOEL for developmental toxicity was 50 mg/kg/day. In a second study, 
    rabbits were dosed by gavage at 0, 62.5, 125, or 250 mg/kg/day on days 
    6 through 19 of gestation. Maternal morbidity, mortality, and clinical 
    signs of toxicity were observed at 250 mg/kg/day. Fetal toxicity, 
    consisting of decreased number of live fetuses per doe, increased early 
    resorptions and post implantation loss was observed at 250 mg/kg/day. A 
    NOEL for maternal and developmental toxicity of 125 mg/kg/day was 
    observed.
        Conclusions: Based on the two-generation reproduction study in 
    rats, ethephon is not considered a reproductive toxicant and shows no 
    evidence of endocrine effects. The data from the developmental toxicity 
    studies on ethephon show no evidence of a potential for developmental 
    effects (malformations or variations) at doses that are not maternally 
    toxic. The NOEL for both maternal and developmental toxicity in rats 
    was 500 mg/kg/day and for rabbits the NOEL for both maternal and 
    developmental toxicity was 50 mg/kg/day, respectively.
        4. Subchronic toxicity. The subchronic toxicity of ethephon has 
    been studied in three human studies and a 21-day dermal study in 
    rabbits. These studies are summarized below:
        a. Male and female subjects received ethephon at doses of 0.17 and 
    0.33 mg/kg/day for 22 days. The daily doses were divided into 3 gelatin 
    capsules. No adverse effects were noted in clinical observations, 
    hematology, serum chemistry (including RBC ChE) and urinalysis. There 
    was a significant decrease in plasma ChE for both treatment groups, 
    although the effect at 0.17 mg/kg/day appeared to be very close to the 
    threshold for significance.
        b. Male and female subjects received ethephon at a dosage of 0.5 
    mg/kg/day for 16 days. The daily dose was divided into 3 gelatin 
    capsules. No adverse effects were noted in clinical observations, 
    hematology, serum chemistry (including RBC ChE) and urinalysis. There 
    was a significant decrease in plasma cholinesterase.
        c. Ethephon was administered to male and female subjects at a daily 
    dose of 124 mg/day (1.8 mg/kg/day average for both sexes) divided up 
    into 3 gelatin capsules for 28 days. Clinical signs of toxicity were 
    observed and included diarrhea, urgency of bowel movements, urinary 
    urgency and stomach cramps. No effects were noted with regard to 
    hematology, urinalysis or serum chemistry including cholinesterase 
    evaluations.
        d. In a 21-day dermal study, 10 rabbits per sex per group were 
    dosed dermally at 0, 25, 75, and 150 mg/kg/day, five days per week for 
    three weeks. Skin effects were observed at all doses. Effects ranged 
    from erythema and desquamation at the lowest dose to acanthosis and 
    chronic inflammation at 150 mg/kg/day. No systemic treatment-related 
    effects were observed on body weight, food consumption, organ weight or 
    histopathology. The systemic NOEL was greater than 150 mg/kg/day.
        Conclusions: Based on the results of the 3 studies in humans, a 
    LOEL of 1.8 mg/kg/day was established in the 28-day study. In the 22-
    day study, 0.17 mg/kg/day appeared to be very close to the threshold 
    for significance. The systemic NOEL in the 21-day dermal study in 
    rabbits was greater than 150 mg/kg/day.
        5. Chronic effects. A 2 year chronic toxicity/oncogenicity study in 
    rats, an 18 month mouse oncogenicity study, a 1-year study in dogs, and 
    a 2-year chronic study in dogs were performed on ethephon technical. 
    These studies are summarized below:
        a. A combined chronic/oncogenicity study was performed on ethephon 
    in Sprague-Dawley rats. Doses administered in the feed were 0, 300, 
    3,000, 10,000 or 30,000 ppm for 95 weeks to the males and 103 weeks for 
    the females. The doses administered relative to body weight were 0, 13, 
    131, 446, or 1,416 mg/kg/day for males and 0, 16, 161, 543 or 1,794 mg/
    kg/day for females. Plasma and erythrocyte cholinesterase was inhibited 
    at all doses (NOEL<300 ppm).="" brain="" cholinesterase="" inhibition="" was="" not="" observed.="" a="" decrease="" in="" male="" body="" weight="" was="" observed="" at="" 10,000="" ppm.="" at="" 30,000="" ppm="" a="" body="" weight="" decrease="" was="" observed="" in="" both="" sexes.="" additional="" effects="" at="" 30,000="" ppm="" were="" thyroglossal="" duct="" cysts,="" kidney="" glomerulo-sclerosis="" and="" nephritis="" and="" biliary="" hyperplasia="" cholangiofibrosis.="" no="" carcinogenic="" effects="" were="" observed.="" b.="" male="" and="" female="" cd-1="" mice="" were="" administered="" ethephon="" in="" the="" diet="" at="" 0,="" 100,="" 1,000,="" or="" 10,000="" ppm="" (0,="" 15.5,="" 156,="" or="" 1,630="" mg/kg/day)="" for="" 78="" weeks.="" an="" additional="" dose="" level="" of="" 50,000="" ppm="" was="" terminated="" at="" 12="" weeks="" because="" of="" excessive="" morbidity="" and="" mortality.="" no="" evidence="" of="" treatment="" related="" tumors="" was="" observed.="" a="" noel="" of="" 15.5="" mg/kg/day="" was="" determined="" for="" plasma="" cholinesterase="" inhibition.="" at="" 1,630="" mg/kg/day="" male="" body="" weights="" were="" increased="" and="" female="" body="" weights="" decreased="" compared="" to="" controls.="" c.="" ethephon="" technical="" was="" administered="" in="" the="" feed="" at="" 0,="" 30,="" 300,="" and="" 3,000="" ppm="" (0,="" 0.75,="" 7.5,="" or="" 75="" mg/kg/day)="" to="" male="" and="" female="" beagle="" dogs="" [[page="" 2152]]="" for="" 2="" years.="" due="" to="" toxicity/morbidity,="" the="" high="" dose="" was="" reduced="" as="" follows:="" 75="" mg/kg/day="" weeks="" 0-3;="" 50="" mg/kg/day="" weeks="" 4-5;="" 25="" mg/kg/day="" weeks="" 6-24;="" 37.5="" mg/kg/day="" weeks="" 25-104.="" plasma="" cholinesterase="" was="" inhibited="" at="" all="" doses=""><0.75 mg/kg/day).="" a="" noel="" for="" erythrocyte="" cholinesterase="" inhibition="" of="" 0.75="" mg/kg/day="" with="" a="" loel="" of="" 7.5="" mg/kg/="" day="" was="" observed.="" histopathology="" showed="" smooth="" muscle="" atrophy="" in="" the="" gut="" at="" 7.5="" mg/kg/day="" with="" a="" noel="" of="" 0.75="" mg/kg/day.="" d.="" ethephon="" was="" administered="" in="" the="" feed="" at="" doses="" of="" 0,="" 100,="" 300,="" 1,000="" or="" 2,000="" ppm="" (0,="" 2.7,="" 8.2,="" 28.5,="" or="" 52.1="" mg/kg/day)="" to="" male="" and="" female="" beagle="" dogs="" for="" 52="" weeks.="" a="" systemic="" noel="" of="" 1,000="" ppm="" (28.5="" mg/="" kg/day)="" was="" observed="" for="" decreased="" spleen="" weight,="" body="" weight,="" hemoglobin="" and="" hematocrit="" in="" males.="" the="" females="" showed="" a="" decreased="" spleen/body="" weight="" ratio="" for="" the="" same="" noel.="" cholinesterase="" inhibition="" was="" not="" determined.="" conclusions:="" the="" noel="" in="" the="" chronic="" rat="" study="" was="" 131="" mg/kg/day="" based="" on="" the="" decreased="" body="" weight="" gains="" in="" males.="" the="" noel="" in="" the="" most="" recent="" one-year="" dog="" study="" was="" determined="" to="" be="" 28.5="" mg/kg/day="" based="" on="" body="" weight,="" organ="" weight="" effects="" and="" hematology="" effects.="" ethephon="" has="" been="" tested="" in="" both="" rats="" and="" mice="" for="" oncogenic="" activity.="" no="" oncogenic="" effects="" were="" observed.="" 6.="" animal="" metabolism.="" rat="" metabolism--ethephon="" technical.="" the="" rat="" metabolism="" study="" consisted="" of="" a="" single="" intravenous="" dose="" group="" at="" 50="" mg/kg,="" and="" single="" and="" multiple="" oral="" high="" dose="" groups="" at="" 50="" and="" 1,000="" mg/kg.="" the="" oral="" cmax="" (maximum="" concentrations="" were="" reached="" at="" 1.3="" and="" 1="" hours="" for="" the="" 50="" mg/="" kg="" dose="" and="" 1.9="" and="" 2.5="" hours="" for="" the="" 1,000="" mg/kg="" dose="" in="" males="" and="" females,="" respectively.="" the="" t1/2="" of="" the="" rapid="" excretion="" phase="" (a-phase)="" at="" the="" 50="" mg/kg="" dose="" was="" 7="" hours="" for="" both="" sexes="" and="" 4="" and="" 9="" hours="" at="" 1,000="" mg/kg="" for="" the="" males="" and="" females,="" respectively.="" oral="" and="" intravenous="" doses="" were="" rapidly="" excreted="" in="" the="" urine="" accounted="" for="" 48="" to="" 71="" percent="" of="" the="" administered="" radioactivity.="" approximately="" 7="" percent="" was="" excreted="" in="" the="" feces.="" exhaled="" ethylene="" was="" 10-20="" percent="" and="">2 was less than 1 percent of the administered dose. The 
    highest tissue concentrations were found in the blood, bone, liver, 
    kidney and spleen with no significant differences between single and 
    multiple dosing. No significant differences were observed in the 
    excretion pattern with either sex or multiple dosing.
        Goat metabolism--Ethephon technical. In a goat metabolism study, 
    ethephon was incorporated into natural products (glutathione 
    conjugates, protein, glycogen, and triglycerides) and expired as 
    CO2 and ethylene.
        Hen metabolism--Ethephon technical. In a hen metabolism study, 
    ethephon metabolism involved an initial removal of chlorine to form 2-
    hydroxyethanephosphonic acid followed by further metabolism which 
    results in the release of ethylene and carbon dioxide as well as 
    intermediates which can enter into fundamental biochemical pathways 
    leading to the biosynthesis of proteins and lipids.
        Conclusions: Ethephon technical is not metabolized to breakdown 
    products that can be reasonably expected to present any chronic dietary 
    risk.
        7. Metabolite toxicology. Ethephon degrades to ethylene phosphate 
    and chloride. Therefore, no significant toxicity is anticipated from 
    these breakdown/metabolites.
        8. Neurotoxicity. The acute neurotoxicity of ethephon has been 
    studied. The study is summarized below:
        Groups of 12 male and 12 female Sprague Dawley rats were treated 
    once by gavage with ethephon at dose levels of 0, 500, 1,000, or 2,000 
    mg/kg in order to assess its potential acute neurotoxicity. The time 
    for assessing peak behavioral effects was previously determined in 
    another study to be approximately 6 hours post dosing. At 2,000 mg/kg, 
    mortality (females only) and transitory effects including pupillary 
    constriction, increased urination (males only), reduced food 
    consumption and body weight, decreased body temperature (females only), 
    and reduced motor activity. Mortality and reduced food consumption was 
    also observed for the 1,000 mg/kg females, motor activity was decreased 
    for the 1,000 mg/kg males and constricted pupils were noted for some 
    animals in all the lower dosage groups. No neuropathological lesions 
    were seen that were attributed to treatment with ethephon. The nature 
    of the findings suggests that they were generally isolated 
    pharmacological effects and not of neurotoxicological significance 
    given their transitory nature and the lack of treatment related 
    structural lesions in the nervous system.
        Conclusions: The acute neurotoxicity study demonstrated transient 
    findings that suggested isolated pharmacological effects and no NOEL 
    was established based on the observation of transient constricts. 
    Ethephon does not appear to pose any significant acute neurotoxicity.
    
    C. Aggregate Exposure
    
        1. Dietary exposure.  a. Food - Ethephon is registered for use on 
    the following food crops: cotton, apples, cherries, tomatoes, wheat, 
    barley, peppers, grapes, tobacco, walnuts, almonds, blackberries, 
    cantaloupe, pineapple, sugarcane and macadamia nuts. In addition, IR-4 
    is conducting work to support new uses on blueberries, coffee, 
    cranberries, figs and guavas. Ethephon has several ornamental/non-food 
    applications as well. All residue requirements cited in the ethephon 
    RED have been submitted to EPA. As a result of this work, increased 
    tolerances have been proposed for cottonseed (6 ppm, PP 6F4743) and 
    cotton gin by-products (180 ppm, amendment to PP 1H5603). As part of 
    the reregistration process, the following tolerances will be revoked: 
    cucumbers, filberts, lemons, pineapple forage and fodder, pumpkins, 
    tangerines, tangerine hybrids and sugarcane molasses. The tolerances 
    for residues of ethephon in or on food and feed commodities are 
    currently based in terms of ethephon per se. An enforcement method was 
    submitted to EPA for determination of residues of ethephon in/on plant 
    commodities and in milk, ruminant and poultry tissues. The ethephon RED 
    lists the number of treated acres by crop for all major ethephon uses 
    in the U.S.
        b. Drinking water - Based on the available studies and the use 
    pattern, Rhone-Poulenc does not anticipate residues of ethephon in 
    drinking water. There is no established Maximum Concentration Level or 
    Health Advisory Level for ethephon under the Safe Drinking Water Act.
        2. Non-dietary. The potential for non-occupational exposure to the 
    general public is also insignificant since only approximately 800 lbs 
    of ethephon technical is sold in the U.S. home and garden market 
    annually. The residential lawn or garden uses anticipated for these 
    products where the general population may be exposed via inhalation or 
    dermal routes are negligible. The home and garden formulation that is 
    sold in the U.S. contains only 3.9 percent ethephon which would further 
    limit exposure.
    
    D. Cumulative Effects
    
        While ethephon is an inhibitor of ChE of the plasma and RBC, it has 
    not demonstrated any ability to inhibit brain ChE in rats, mice, or 
    dogs under condition of a chronic dietary dosing regimen. Furthermore, 
    unlike classic organophosphate ChE inhibitors, ethephon did not induce 
    symptoms of ChE inhibition, such as constriction of the pupils, 
    salivation, lacrimation, diarrhea, urination, tremors, and convulsions 
    under chronic feeding of
    
    [[Page 2153]]
    
    doses up to 30,000, 10,000, and 2,000 ppm in the rat, mouse, and dog, 
    respectively. In the rat study, the plasma and RBC ChE were inhibited 
    approximately 55 percent and 85 percent, respectively. In the mouse 
    study, both peripheral ChEs were inhibited by approximately 70 percent. 
    Although cholinesterase determinations were not performed in the 1 year 
    dog study, in a 2 year dog study, plasma and RBC ChE were inhibited 60 
    percent and 70 percent, respectively. Despite these high degrees of 
    inhibition of peripheral ChE, no clinical signs or symptoms consistent 
    with ChE inhibition occurred in these studies. It is generally only 
    under very extreme conditions such as high doses administered via oral 
    gavage or under occlusive dermal dressing in rabbits in which signs 
    that are consistent with ChE inhibition are observed. These clinical 
    signs generally occur at doses that produce acute lethality. However, 
    these signs may in fact be unrelated to CNS ChE inhibition and could be 
    a non-specific reaction to the acidic and therefore highly irritant 
    nature of ethephon.
        Ethephon should not be regarded as a classical inhibitor of ChE 
    such as the carbamates and organophosphates since it does not produce 
    the typical nervous system effects of those compounds. The recently 
    updated chronic data base adequately proves that very high dietary 
    doses of ethephon do not inhibit brain ChE, that it does not produce 
    the classical clinical signs of ChE inhibition, and that it does not 
    produce life-shortening effects, despite moderate to severe lifetime 
    inhibition of both plasma and RBC ChE. The inhibition of ChE by 
    ethephon is only an indicator of exposure and is not a measure of its 
    potential for inducing ChE-mediated toxicity.
        In summary, Rhone-Poulenc concludes that consideration of a common 
    mechanism of toxicity is not appropriate at this time since there is no 
    significant toxicity observed for ethephon. Even at high doses, 
    ethephon does not act as a classical inhibitor of cholinesterase. 
    Exposure, even at high doses, does not lead to brain cholinesterase 
    inhibition. There is no reliable data to indicate that the effects 
    noted would be cumulative with those of organophosphate or carbamate-
    type compounds. Therefore, Rhone-Poulenc has considered only the 
    potential risks of ethephon in its exposure assessment.
    
    E. Safety Determination
    
        The EPA OPP/HED RfD Peer Review Committee determined that the 
    reference dose (RfD) should be based on the 28-day study in humans. 
    Using the LOEL of 1.8 mg/kg/day in this study and an uncertainty factor 
    (UF) of 100 to account for intraspecies variability and the lack of a 
    NOEL, an RfD of 0.018 mg/kg/day was established as the chronic dietary 
    endpoint.
        1. U.S. population--General. A chronic dietary risk assessment 
    which included all proposed changes in ethephon tolerances was 
    conducted on ethephon using two approaches: (1) a Tier 1 approach using 
    tolerance-level residues for all foods included in the analysis, and 
    (2) Monte Carlo simulations using tolerance-level residues for all 
    foods adjusted for percent crop treated (Tier 3). Using the Tier 1 
    approach, MOEs at the 95th and 99th percentiles of exposure for the 
    overall U.S. population were 25 and 9, respectively. Using Tier 3 
    procedures in which residues were adjusted for the percent of the crop 
    treated, MOEs were 114 and 42, respectively. Acute exposure was also 
    estimated for infants and children 1 to 6 years of age. In the Tier 1 
    analysis, the most highly exposed subgroup was infants. For this 
    population, MOEs at the 95th and 99th percentiles of exposure were 7 
    and 4, respectively. Using the Tier 3 method MOEs were 56 and 12, 
    respectively. Even under the conservative assumptions presented here, 
    the more realistic estimates of dietary exposure (Tier 3 analyses) 
    clearly demonstrate adequate MOEs up to the 99th percentile of exposure 
    for all population groups analyzed.
        2. Infants and children. In assessing the potential for additional 
    sensitivity of infants and children to residues of ethephon, the 
    available developmental toxicity and reproductive toxicity studies and 
    the potential for endocrine modulation by ethephon were considered. 
    Developmental toxicity studies in two species indicate that ethephon is 
    not a teratogen. The 2 generation reproduction study in rats 
    demonstrated that there were no adverse effects on reproductive 
    performance, fertility, fecundity, pup survival, or pup development. 
    Maternal and developmental NOELs and LOELS were comparable, indicating 
    no increase in susceptibility of developing organisms. No evidence of 
    endocrine effects were noted in any study. It is therefore concluded 
    that ethephon poses no additional risk for infants and children and no 
    additional uncertainty factor is warranted. FFDCA section 408 provides 
    that an additional safety factor for infants and children may be 
    applied in the case of threshold effects. Since, as discussed in the 
    previous section, the toxicology studies do not indicate that young 
    animals are any more susceptible than adult animals and the fact that 
    the proposed RfD calculated from the LOEL from the 28 day human study 
    already incorporates an additional uncertainty factor, Rhone-Poulenc 
    believes that an adequate margin of safety is therefore provided by the 
    RfD established by EPA. Additionally, this LOEL is also 8X lower than 
    the next lowest NOEL (2 generation reproduction study, NOEL=15 mg/kg/
    day) in the ethephon toxicology data base. Ethephon has no endocrine-
    modulation characteristics as demonstrated by the lack of endocrine 
    effects in developmental, reproductive, subchronic, and chronic 
    studies.
        Conclusion: A dietary Risk assessment was submitted to EPA in 
    September, 1996 (MRID #44100203). An RfD of 0.018 mg/kg/day has been 
    established by EPA based on the LOEL in the 28-day human study. 
    Adequate MOEs exist for all populations including infants and children. 
    No additional uncertainty factor for infants and children is warranted 
    based on the completeness and reliability of the database, the 
    demonstrated lack of increased risk to developing organisms, and the 
    lack of endocrine-modulating effects.
    
    F. International Tolerances
    
        The Codex MRL for grapes is 10 mg/kg verses 2 ppm for U.S. 
    tolerance. The tomato Codex MRL is 3 mg/kg verses 2 ppm for the U.S. 
    tolerance. All other U.S. tolerances are identical to corresponding 
    Codex MRLs.
    
    II. Administrative Matters
    
        Interested persons are invited to submit comments on the this 
    notice of filing. Comments must bear a notation indicating the document 
    control number, [PF-686]. All written comments filed in response to 
    this petition will be available in the Public Response and Program 
    Resources Branch, at the address given above from 8:30 a.m. to 4 p.m., 
    Monday through Friday, except legal holidays.
        A record has been established for this notice under docket number 
    [PF-686] including comments and data submitted electronically as 
    described below). A public version of this record, including printed, 
    paper versions of electronic comments, which does not include any 
    information claimed as CBI, is available for inspection from 8:30 a.m. 
    to 4 p.m., Monday through Friday, excluding legal holidays. The public 
    record is located in Rm. 1132 of the Public Response and Program 
    resources Branch, Field Operations Division (7506C), Office of 
    Pesticide Programs, Environmental Protection Agency, Crystal Mall #2, 
    1921 Jefferson Davis highway, Arlington, VA.
    
    [[Page 2154]]
    
        Electronic comments can be sent directly to EPA at:
        opp-docket@epamail.epa.gov
    
    
        Electronic comments must be submitted as ASCII file avoiding the 
    use of special characters and any form of encryption.
        The official record for this rulemaking, as well as the public 
    version, as described above will be kept in paper form. Accordingly, 
    EPA will transfer all comments received electronically into printed, 
    paper form as they are received and will place the paper copies in the 
    official rulemaking record which will also include all comments 
    submitted directly in writing. The official rulemaking record is the 
    paper record maintained at the address in ``ADDRESSES'' at the 
    beginning of this document.
    
    List of Subjects
    
        Environmental protection, Administrative practice and procedure, 
    Agricultural commodities, Pesticides and pests, Reporting and 
    recordkeeping requirements.
    
        Dated: January 7, 1997.
    
    Stephen L. Johnson,
    Director, Registration Division, Office of Pesticide Programs.
    
    [FR Doc. 97-983 Filed 1-14-97; 8:45 am]
    BILLING CODE 6560-50-F
    
    
    

Document Information

Published:
01/15/1997
Department:
Environmental Protection Agency
Entry Type:
Notice
Action:
Notice of filing.
Document Number:
97-983
Dates:
Comments, identified by the docket number [PF-686], must be received on or before, February 14, 1997.
Pages:
2149-2154 (6 pages)
Docket Numbers:
PF-686, FRL-5580-3
PDF File:
97-983.pdf